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Abstract 
Aim. To examine and compare the composition and the oxidisability of the hydrophobic 
core and amphipathic surface of lipoproteins in a group of adult males with metabolic 
syndrome before and after weight loss of at least 5% of their initial weight following a 
hypocaloric diet. 
Methods. The concentration of cholesterol, triglycerides, phospholipids, and proteins was 
studied to analyse the chemical composition of lipoproteins. Pyrenyl-cholesteryl ester and 
pyrenyl-phosphatidylcholine, incorporated into the hydrophobic core or amphipathic 
surface of LDL and HDL, respectively, were used for measuring 2,2'-azobis-2-methyl-
propanimidamide-dihydrochloride-induced peroxidation kinetics in these regions. 
Results. In comparison with the initial time, there was an improvement of HDL oxidisability 
with an increase of lag-time and a reduction of the velocity of propagation of peroxidation 
in the core of HDL. Parallel but opposite, there was a worsening in the susceptibility to 
peroxidation of LDL with a reduction in lag-time and an increased propagation rate of 
peroxidation in the LDL core. After weight loss, LDL showed a higher content of 
triglycerides whereas HDL showed reduced triglycerides content. In both LDL and HDL, 
the increase in the percentage of triglycerides was connected with an increased 
propagation rate of peroxidation kinetic and with a reduction of the lag-time in the 
hydrophobic core. 
Conclusions. A more detailed knowledge of the chemical composition and oxidisability of 
both the surface and core of lipoproteins could be a useful additional means for better 
understanding the mechanisms that link the changes in lipoproteins metabolism to the 
risk of cardiovascular disease in patients with metabolic syndrome after weight loss. 
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Introduction 
Obesity and metabolic syndrome receive more attention every day. The increase in the 
number of people with metabolic syndrome now represents a serious problem for national 
health systems. 
In subjects with metabolic syndrome, there is a clear increase of general low grade 
inflammation and consequently an increase of oxidative stress. Inflammation and 
oxidative stress are closely linked and influence each other. At the same time 
inflammation and oxidative stress affect the properties and functions of lipoproteins. The 
alteration in lipids metabolism, inflammation and oxidative stress increase the risk of 
metabolic disorders, such as type 2 diabetes, the risk of cardiovascular disease, and so 
on. 
A thorough study of the metabolic syndrome requires a multidisciplinary approach. The 
study of lipoproteins and lipid metabolism offers an unusual and privileged perspective 
with which to analyse metabolic syndrome. Lipoproteins are a bridge between the 
biochemical and metabolic aspects of "syndrome X" and the clinical aspects related to 
arteriosclerosis, cardiovascular risk and heart disease. If it is true that the study of 
lipoproteins provides an inherently multidisciplinary overview, studying and using them in 
the laboratory requires a solid basis of biochemistry for understanding lipoproteins 
metabolism and the oxidative alterations of their components. Also, with regard to weight 
loss, it is important to deepen the argument on different theoretical levels and start 
understanding clinical aspects prior to changes in lipoproteins metabolism. Lipoproteins 
again offer a privileged although complex view of the problem. 
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Obesity, metabolic syndrome and inflammation 
In the 1980s, Reaven proposed that patients with high blood pressure, hyperinsulinaemia, 
impaired glucose tolerance, increased plasma triglycerides concentrations and 
decreased high density lipoproteins cholesterol concentrations had a plurimetabolic 
syndrome which, at the time, was described as syndrome X, and is commonly referred to 
as the metabolic syndrome [1]. 
Several different sets of criteria have been proposed during the past decades for the 
diagnosis of the metabolic syndrome [2]. The original World Health Organization (WHO) 
recommendations were not designed to be an exact definition, but were formulated as a 
working guideline to be improved in the future. The recommendations were part of a 
WHO report on the definition, diagnosis and classification of diabetes. The WHO 
definition is based on the assumption that insulin resistance is one of the major underlying 
contributors to the metabolic syndrome. Following the publication of the WHO definition in 
1999, the European Group for the Study of Insulin Resistance (EGIR) proposed a 
modified version to be used in non-diabetic subjects only, which is simpler to use in 
epidemiological studies since it does not require a euglycaemic clamp to measure insulin 
sensitivity. 
The National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) 
definition was presented in 2001 as part of an educational program for the prevention of 
coronary heart disease [3]. This definition was designed to facilitate diagnosis in clinical 
practice and differed in two major ways from other definitions. First, it did not include a 
measure of insulin resistance as a component, and second, it was not glucose-centric, 
and treated glucose abnormalities as being of equal importance to other components in 
making the diagnosis. The NCEP-ATP III guidelines state that the metabolic syndrome 
may be diagnosed when a person has three or more of the five diagnostic components. 
These components are: central obesity, an elevated TG level, a reduced HDL-cholesterol 
level, elevated blood pressure and an elevated fasting glucose concentration. 
Importantly, the NCEP-ATP III definition includes waist circumference as the measure of 
obesity. The NCEP-ATP III criteria for the metabolic syndrome have been widely used in 
both clinical practice and epidemiological studies. Alberti et al. [4] studied the difference 
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in prevalence rates for the metabolic syndrome using these three definitions, starting with 
a large Australian work of lifestyle and glucose intolerance. Only 9% of the individuals 
studied met the criteria for all three definitions, although each of the three definitions 
identified approximately 16-21% of the Australian population as having metabolic 
syndrome. Figure 1 shows the overlaps of the prevalence data obtained with the three 
different sets of criteria. 
Figure 1 - This graph shows the prevalence of the metabolic syndrome observed in the Australian population 
using WHO, EGIR, and NCEP-ATP III definitions and their overlaps [4]. 
In 2005, the International Diabetes Federation (IDF) proposed a new classification that 
included central obesity as an essential element for diagnosis, changing the parameters 
of waist circumference [5]. The NCEP-ATP III definition and the IDF definition of the 
metabolic syndrome do not identify the same patients. The metabolic syndrome defined 
by NCEP-ATP III criteria confers a higher risk of vascular events than the metabolic 
syndrome defined by IDF criteria. The IDF wanted its new definition to encourage the 
identification of patients at increased risk of cardiovascular events. Therefore, there are 
important differences between the NCEP-ATP III and IDF definitions of the metabolic 
syndrome that may explain the weaker association of the IDF metabolic syndrome with 
vascular events. First, the lowering of the cut-off value for waist circumference leads to 
the inclusion of patients with a relatively lower level of this risk factor in the IDF category 
of the metabolic syndrome. Second, the mandatory status of the waist criterion in the new 
definition results in a relatively lower prevalence of other (potentially stronger) metabolic 
syndrome risk factors in patients with the metabolic syndrome. In particular, the high 
triglycerides and low HDL cholesterol metabolic syndrome components are relatively 
underrepresented in patients with IDF-defined metabolic syndrome. However, the 
greatest vascular risk in our investigation was conferred by these lipid traits [2]. 
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Table 1 - Diagnostic criteria for metabolic syndrome according to NCEP-ATP III [3] and according to IDF [5]. 
NCEP-ATP III (2001) IDF (2005) 
Waist circumference 
• ≥ 102cm in men 
• ≥ 88cm in women  
 
Triglycerides ≥ 150 mg/dl or drug treatment  
 
HDL cholesterol  
• < 40 mg/dl in men 
• < 50 mg/dl in women 
 
Blood pressure 
• ≥ 130 mm Hg systolic or 
• ≥ 85 mm Hg diastolic 
 
Or drug treatment for hypertension  
 
Fasting glucose ≥ 110 mg/dl or previous 
diagnosis of type 2 diabetes  
Waist circumference 
• ≥ 94 cm in men 
• ≥ 80 cm in women 
 
Triglycerides ≥ 150 mg/dl or drug treatment  
 
HDL cholesterol 
• < 40 mg/dl in men 
• < 50 mg/dl in women 
 
Blood pressure 
• ≥ 130 mm Hg systolic or 
• ≥ 85 mm Hg diastolic 
 
Or drug treatment for hypertension 
 
Fasting glucose ≥ 110 mg/dl or previous 
diagnosis of type 2 diabetes 
Prospective population studies show that the metabolic syndrome confers a 2-fold 
increase in relative risk for atherosclerotic events, and in individuals without established 
type 2 diabetes mellitus, a 5-fold increased risk for developing diabetes when compared 
with people without this syndrome. This implies that the metabolic syndrome imparts a 
relatively high long-term risk for both atherosclerotic cardiovascular disease and diabetes 
[3]. 
At present, it is not clear whether the metabolic syndrome has a single cause, and it 
appears that it can be precipitated by multiple underlying risk factors. The most important 
of these underlying risk factors are abdominal obesity and insulin resistance. The 
abdominal visceral adipose tissue is a source of cytokines and adipokines, which 
influence interactions between the immune system and the vascular wall, inducing a state 
of chronic inflammation and increased oxidative stress [6]. When the picture is 
complicated by changes in carbohydrate and lipid metabolism, the risk factors for 
cardiovascular and cerebrovascular disease, which are already high in a state of 
uncomplicated obesity, are increased. It is still not clear what the alteration is, but it 
seems increasingly clear that the single alteration should be able to influence others, 
defining a complex inflammatory state, as that of the metabolic syndrome. Atherogenic 
dyslipidaemia, described as the combination of raised triglycerides and small dense LDL 
and HDL particles, is an independent and important risk factor for coronary heart 
disease. In metabolic syndrome, the lipid perturbations are amplified by immune system 
activation and insulin resistance, indicating a sort of vicious circle with important and 
complex interactions that promote the development of atherosclerosis [7]. Atherosclerosis 
is an inflammatory disease characterised by vascular wall infiltration by macrophages 
and T cells associated with lipid infiltration [8]. Implication of the immune system in 
atherosclerosis is still incompletely understood, but recent works have highlighted the 
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role of the innate immune system in generating a response in the presence of tissue 
aggression, which would subsequently lead to the activation of inflammatory pathways 
[9]. Therefore, the metabolic perturbations that mediate important and complex 
interactions with the immune system and the vascular wall in relation with atherosclerosis 
are reviewed, with particular emphasis on the mechanisms that mediate immune 
activation. The immunological paradigm has been challenged in the 1990s with the 
danger model of immunity, in which the immune system responds to damaged cells 
rather than to foreign ones [10]. This model of immunity has allowed expansion of the 
scope of immunological implication in diseases with an inflammatory component that 
might be detrimental to the host. The discovery at the end of the 20th century of the Toll-
like receptors (TLR) in mammalian innate immune cells including macrophages and 
dendritic cells has reinforced the view that the innate immune system plays a key role in 
inflammatory response [11]. Furthermore, the discovery that, beside bacterial products, 
endogenous substances such as oxidised LDL and heat shock proteins mediate the 
activation of TLR has reinforced the view that the innate immune system plays a key role 
in the genesis of atherosclerosis [12]. Therefore, immune cells are the gatekeepers that 
detect cellular damage and initiate a response allowing our body to defend against 
‘offending’ insults. 
Endogenous danger signals are from intracellular or secreted extracellular products. 
Some are constitutive, whereas others are inducible and require either neosynthesis or 
modifications before they can activate the innate immune system. Atherosclerosis is 
characterised by a chronic inflammatory state in which interplay between metabolic 
factors and cytokines leads to stimulation of the innate immune system when these 
signals are detected as a danger. Therefore, signals from different sources including 
modified lipid products, endogenous inducible factors, and cytokines are implicated in a 
complex inflammatory response that relies on tissue damage as the primary stimulating 
event, leading to immune activation. 
There is also an evolutionary perspective that could explain why metabolic disorders are 
linked to inflammation. The ability to extract and store energy from food and the possibility 
to protect themselves from infection are indispensable for the survival of any form of life. It 
is highly likely that metabolic and immune functions have evolved from a common 
ancestral structure. For example, the Drosophila fat body performs functions that can be 
compared to the liver and the haematopoietic and immune systems in humans. It is 
possible to imagine a situation in which common or overlapping pathways regulate both 
metabolic and immune functions through common key regulatory molecules and 
signalling systems [13]. 
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Lipoproteins metabolism 
Cholesterol, cholesteryl esters, triglycerides and phospholipids are essentially insoluble in 
water. These lipids must be transported from the tissues where they are produced to 
those in which they are stored or used. They are transported through the plasma in 
macromolecular aggregates, called lipoproteins, consisting of specific transporter 
proteins, called apolipoproteins, which combine different proportions of phospholipids, 
cholesterol, cholesterol esters and triglycerides [14]. Lipoproteins have a spherical 
structure containing a hydrophobic core of lipids with the hydrophilic side chains of the 
amino acids of apolipoproteins on the outside and a surface layer composed of 
phospholipids with the fatty acids oriented toward the core of the particle. The different 
combinations of lipids and proteins generate particles with densities ranging from that of 
chylomicrons, the lowest, to that of high density lipoproteins, the highest. Based on these 
differences in density, the particles can be separated by ultracentrifugation. The 
classification of serum lipoproteins has evolved historically through several phases 
corresponding with the development of different laboratory methodologies. With the 
arrival of the analytical ultracentrifugation in the 1940s, lipoproteins were classically 
separated into four major classes designated as chylomicrons (exogenous triglycerides 
rich particles of d <0.94 g/ml), very low density lipoproteins (VLDL, endogenous 
triglycerides rich particles of d=0.94-1.006 g/ml), low density lipoproteins (LDL 
cholesteryl ester rich particles of d=1.006-1.063 g/ml), and high density lipoproteins (HDL 
particles containing approximately 50% protein of d=1.063-1.21 g/ml). With subsequent 
improvements in ultracentrifugation techniques, further heterogeneity was detected within 
each of those major lipoprotein classes; this resulted in the need for further subdivision 
into several density subclasses such as HDL2a (d=1.10-1.125 g/ml), HDL2b (d=1.063-
1.10 g/ml), and HDL3 (d=1.125-1.21 g/ml). There is no doubt that the separation of 
lipoproteins by ultracentrifugation has been essential for the advances in this field [15]. 
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Figure 2 - (a) Structure of a low-density lipoprotein. (b) The four classes of lipoproteins viewed in the electron 
microscope after negative staining. Chylomicrons 50-200 nm, VLDL 28-70 nm; LDL 20-25 nm, HDL 8-11 nm 
[14]. 
 
Table 2 - Apolipoproteins of human plasma lipoproteins [16]. 
 
Apolipoproteins Molecular 
mass 
Association with 
lipoproteins 
Function 
ApoA-I 28 331 HDL Activates LCAT; interacts with the ABC transporter. 
ApoA-II 17 380 HDL Inhibits LCAT. 
ApoA-IV 44 000 Chylomicrons, HDL Activates LCAT; transport/removal of cholesterol. 
ApoB-48 240 000 Chylomicrons Transport/removal of cholesterol. 
ApoB-100 513 000 VLDL, LDL Binds to the receptor for LDL. 
ApoC-I 7 000 VLDL, HDL  
ApoC-II 8 837 Chylomicrons, VLDL, HDL Activates lipoprotein lipase. 
ApoC-III 8 751 Chylomicrons, VLDL, HDL Inhibits lipoprotein lipase. 
ApoD 32 500 HDL  
ApoE 34 145 Chylomicrons, VLDL, HDL Promotes the removal of the VLDL and chylomicrons remnant. 
 
LCAT = Lecithin-Cholesterol Acyl Transferase, VLDL = Very Low Density Lipoprotein, LDL = Low Density 
Lipoprotein, HDL = High Density Lipoprotein. ABC = ATP-Binding/Cassette. 
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Each class of lipoprotein has a specific function determined by the site in which it was 
synthesised and by its composition in lipids and apolipoproteins. In human plasma, at 
least nine different types of apolipoproteins were detected, which were distinguishable by 
size, interactions with specific antibodies and a characteristic distribution in the different 
lipoprotein classes. The protein components act as signals that direct lipoproteins to 
specific tissues or activate enzymes which act on lipoproteins themselves. 
Chylomicrons are the largest and the less dense lipoproteins, as they contain a high 
proportion of triacylglycerol. They are synthesised in the smooth endoplasmic reticulum of 
epithelial cells lining the small intestine, and by moving through the lymphatic system, 
they enter the bloodstream through the thoracic duct and the left subclavian vein. The 
apolipoproteins of chylomicrons are ApoB-48 (specific for this class of lipoproteins), 
ApoE, and ApoC-II. ApoC-II activates the lipoprotein lipase of the capillaries of adipose 
tissue, heart, and skeletal muscle tissue of the mammary gland during lactation, allowing 
the release of fatty acids to the tissues. Chylomicrons carry fatty acids ingested in the diet 
to those tissues in which these compounds are degraded to produce energy or to be 
deposited as an energy reserve. The remnant chylomicrons are now deprived of 
triacylglycerol, but still contain cholesterol, ApoE and ApoB-48. The remnant 
chylomicrons, which are linked by specific receptors for ApoE, arrived at the liver through 
the bloodstream, and mediate uptake through endocytosis. Within the liver, the remnant 
chylomicrons release cholesterol and are degraded in lysosomes.  
When the diet contains more fat than is immediately necessary, lipids are converted into 
triglycerides in the liver and transferred to specific lipoproteins, forming very low density 
lipoproteins (VLDL). Even the carbohydrates can be transformed into triacylglycerol in the 
liver and exported through the VLDL. Besides triglycerides, VLDL contain cholesterol, 
cholesteryl esters and the apolipoproteins ApoB-100, ApoC-I, ApoC-II, ApoC-III and 
ApoE. These lipoproteins are transferred from the liver into the blood, to the muscle and 
to adipose tissue, where the activation of lipoprotein lipase operated by ApoC-II 
determines the release of free fatty acids from the triacylglycerols of VLDL. Most of the 
remnant VLDL is removed from the bloodstream by hepatocytes. As in the case of 
chylomicrons, their intake is mediated by receptors and is dependent on the presence of 
ApoE in remnant VLDL. 
With the loss of triglycerides, VLDL are converted in remnant VLDL (also called 
intermediate density lipoproteins, IDL) that, with the further removal of triacylglycerols, are 
converted into low density lipoproteins (LDL). The LDL are very rich in cholesterol and 
cholesteryl esters and ApoB-100 is their main apolipoprotein. They carry cholesterol to 
extrahepatic peripheral tissues that possess a specific receptor to recognise ApoB-100. 
The apolipoprotein B-100 is a single polypeptide chain, among the longest of which are 
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known to be formed by a sequence of 4636 amino acids and a molecular weight of 513 
000 Da. An LDL particle contains a core of about 1500 molecules of cholesteryl ester, 
surrounded by an envelope of approximately 500 molecules of cholesterol and 800 
phospholipid molecules, as well as a single molecule of ApoB-100. Apo B-100 is 
recognised by specific protein receptors, called LDL receptors, on the surface of cells 
that need to take-in cholesterol. The binding of LDL to their receptor triggers the process 
of endocytosis that transfers LDL and its receptor within the cell, inside an endosome. 
The endosome then merges with a lysosome containing enzymes that hydrolyse 
cholesteryl esters, releasing cholesterol and fatty acids into the cytosol. Even ApoB-100 
of LDL is degraded into amino acids that are released into the cytosol, while the LDL 
receptor is not degraded and returns to the surface of the cell, thereby starting again the 
endocytosis process of LDL. ApoB-100 is also present in VLDL, but its LDL receptor 
binding domain is not available and the conversion of VLDL in LDL exposes the binding 
domain of the receptor for apoB-100. 
The fourth type of lipoprotein, called high-density lipoprotein (HDL), has its origin in the 
liver and small intestine in the form of small particles that are rich in protein and contain 
limited quantities of cholesterol, but no cholesteryl esters. The HDL contain, among 
others, the apolipoproteins ApoA-I, ApoC-I, ApoC-II and also the lecithin-cholesterol 
acyltransferase (LCAT) enzyme that catalyses the formation of cholesteryl ester using 
lecithin and cholesterol. LCAT is present on the surface of HDL and converts the 
cholesterol of chylomicrons and remnant VLDL into cholesteryl ester, which lies within the 
HDL. In this way, the HDL particles undergo a change in shape from a flat disc to a ball, 
which is the typical structure of mature HDL. The HDL rich in cholesterol return to the liver 
where the cholesterol is unloaded. HDL can be picked up by the liver by receptor-
mediated endocytosis, but at least part of the cholesterol contained in HDL is released 
into other tissues through different mechanisms. HDL can bind to a membrane receptor 
called SR-BI in hepatic tissue and in steroidogenic tissues such as the adrenal gland. 
This type of receptor endocytosis is not common, but provides a partial and selective 
transfer of cholesterol and other lipids from HDL to the cells. The HDL, so drained, 
dissociates from the receptor and goes back into circulation to extract other lipids from 
the remnant chylomicrons and VLDL remnants. Once emptied, HDL can remove 
cholesterol stored in extrahepatic tissues and transfer it to the liver through the various 
mechanisms of reverse cholesterol transport. Through one of these pathways, the 
interaction of an empty HDL with the SR-BI receptor of a cell that is rich in cholesterol 
determines the passive transport of cholesterol to HDL from the cell surface. Via a second 
mechanism, ApoA-I in the HDL interacts with the active transporter ATP-Binding/Cassette 
1 (ABC1) that is present in cells that are rich in cholesterol. The ApoA-I and presumably 
the entire HDL is taken up by endocytosis and then secreted full of cholesterol to be 
transported to the liver. 
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HDL in subjects with metabolic syndrome 
HDL have been shown to exert a wide spectrum of anti-atherogenic activities, including 
the promotion of reverse cholesterol transport, anti-inflammatory actions in vasculature 
[17] and the protection of LDL against oxidation [18]. Moreover, the capacity of HDL to 
accumulate [19,20] and neutralise [21] or transport oxidised lipids to the liver [22] 
suggests a role for HDL in the detoxification of these molecules in vivo. Recent evidence 
suggests that structural modifications and composition alterations of HDL due to chronic 
inflammation and acute phase responses may result in the loss of the normal biological 
function of these lipoproteins [17,23]. Furthermore, changes in lipid composition 
associated with metabolic syndrome, such as hypercholesterolaemia and 
hypertriacylglycerolaemia, have been shown to influence the anti-atherogenic capacity of 
HDL [17]. 
Oxidative modification of HDL has been suggested to be another pathway that is involved 
in the generation of less functional HDL [24]; however, while LDL oxidation has been 
widely investigated [25,26], information on HDL oxidation and its role in atherogenesis is 
scarce. The oxidation of HDL lipids leads to the formation of a complex mixture of 
chemical compounds [27] such as conjugated dienes, arachidonic acid-derived 
isoprostanes, lipid peroxides, and aldehydes. Some of these aldehydes, such as 
malondialdehyde (MDA), can easily react with lipids and proteins, giving rise to the 
formation of cross-links between lipid tails and amino acids residues, which decrease the 
fluidity of the compartment in which these alterations have taken place. Such alterations 
may impair the activity of apolipoproteins and HDL-associated proteins and, therefore, 
the anti-atherogenic capacity of HDL.HDL is known to undergo dramatic modifications in 
both structure and composition as a result of the concerted actions of the acute-phase 
response and inflammation. The close association between inflammation, oxidative 
stress, dyslipidaemia, and atherosclerosis suggests that such HDL alterations play a 
significant role in disease progression. As a result, HDL particles progressively lose 
normal biological activities and acquire altered properties. Such altered HDL particles 
have been termed “dysfunctional HDL” and it is essential to emphasise that the degree of 
loss of normal HDL function compared with the absence of this function depends on the 
assay used to characterise HDL functionality [28]. Both the plasma levels and 
apolipoprotein content of HDL can be significantly altered during the acute phase as well 
as during acute and chronic inflammation; levels of ApoA-I and ApoA-II decrease, 
whereas those of ApoA-IV and ApoE increase. The decrease in HDL ApoA-I levels in 
inflammatory states is related to both decreased ApoA-I synthesis in the liver and ApoA-I 
replacement in HDL particles by serum amyloid A. In the circulation, serum amyloid A 
does not exist in a free form; it is usually associated with HDL. Elevated plasma levels of 
serum amyloid A are accompanied by elevated levels of lipid-free ApoA-I, probably due 
to the dissociation of ApoA-I from HDL [29,30]. 
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Chronic inflammation that is characteristic of metabolic disease, such as metabolic 
syndrome and type 2 diabetes, is associated with elevated plasma levels of IL-6. As a 
result, the liver produces serum amyloid A, which replaces ApoA-I and paraoxonase 1 in 
HDL. Oxidative stress, hyperglycaemia, and the elevated activity of CETP are other 
important modulators of HDL function. Oxidative stress modifies specific amino acids in 
ApoA-I, whereas hyperglycaemia results in ApoA-I glycation. CETP exchanges 
cholesteryl esters and TG between HDL and triglycerides-rich lipoproteins, such as VLDL 
and LDL; as a result, HDL become enriched in triglycerides. Such enrichment in 
triglycerides induces conformational changes in ApoA-I, which becomes less accessible 
for interaction with other lipoproteins, including LDL, and prevents the elimination of 
oxidised lipids from LDL. Subsequent HDL hydrolysis by hepatic lipase produces small, 
dense HDL that are enriched in triglycerides and in serum amyloid A and contain ApoA-I 
in an incorrect conformation; such HDL possess deficient functionality compared with 
normal HDL particles. 
Apart from its replacement by serum amyloid A, ApoA-I can undergo other modifications 
in circulation. Amino acid residues in ApoA-I, such as methionine, cysteine, tyrosine, and 
lysine residues, can be selectively modified under the action of pro-oxidants that are 
secreted by arterial wall cells and non-enzymatically glycosylated in the presence of high 
levels of glucose. Oxidised amino acid residues, including chlorotyrosines, nitrotyrosines 
and oxidised lysine and methionine residues, are present in ApoA-I isolated from plasma 
and from human atherosclerotic lesions; furthermore, the ApoA-I content of chloro- and 
nitrotyrosines is increased in the plasma of patients with cardiovascular disease. 
Myeloperoxidase was recently shown to bind to HDL within human atherosclerotic 
lesions, and biophysical studies revealed that myeloperoxidase binding occurs via 
specific interactions with ApoA-I. This likely facilitates the observed selective targeting of 
ApoA-I for site-specific chlorination and nitration by myeloperoxidase generated reactive 
oxidants in vivo. One apparent consequence of myeloperoxidase catalysed ApoA-I 
oxidation includes the functional impairment of the ability of HDL to promote cellular 
cholesterol efflux via the ABCA1 system. Myeloperoxidase-mediated loss of the 
atheroprotective functional properties of HDL may thus provide a novel mechanism 
linking inflammation and oxidative stress to the pathogenesis of atherosclerosis [31]. 
HDL-associated enzymes, including platelet-activating factor-acetyl hydrolase (PAF-AH), 
paraoxonase 1 (PON1), and lecithin–cholesterol acyltransferase (LCAT), can become 
dysfunctional and/or depleted under inflammatory conditions, in metabolic diseases 
involving low HDL levels (type 2 diabetes, metabolic syndrome), and in premature 
coronary heart disease. HDL provides an amphipathic environment, where PON1 finds an 
optimal location to exert its activity. The complex HDL-PON1 is a repository for potentially 
toxic, hydrophobic components of plasma, notably oxidised lipids. Induction of the acute-
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phase response is associated with decreased PON1 activity, probably due to the 
replacement of PON1 by serum amyloid A [32,33]. Furthermore, decreased PON1 activity 
may be caused by enzyme inactivation as a result of oxidation and/or homocysteinylation 
and/or glycation. Same authors found decreased serum concentrations of PON1 in 
subjects with metabolic syndrome and in patients with type 1 and type 2 diabetes, who 
feature elevated levels of inflammation and oxidative stress. Serum PON1 activity 
decreases with age and is lower in subjects with metabolic syndrome and low HDL, as 
well as in patients with type 2 diabetes and familial hypercholesterolaemia, compared 
with age-matched healthy control subjects. Other authors have reported alterations in 
oxidative stress in patients with metabolic syndrome, who did not have diabetes, and 
even in obese subjects; at the same time, no changes were detected in the activity of the 
enzyme paraoxonase. Moreover, low PON1 activity toward paraoxon has been reported 
to represent an independent risk factor for coronary events in men at high cardiovascular 
risk [34]. HDL-associated PAF-AH activity, expressed as a percentage of total serum 
PAF-AH activity, has been shown to be lower in hypercholesterolaemic patients than in 
control subjects. In the same subjects, in contrast, LDL-associated PAF-AH activity was 
elevated, suggesting a major redistribution of PAF-AH activity in the plasma of 
dislipidaemic individuals from ApoA-I- to ApoB-containing lipoproteins [35]. Although 
apolipoproteins and enzymes are major determinants of altered HDL function, it is 
considerably influenced by changes in lipid content. HDL core enrichment in triglycerides 
with cholesteryl esters depletion is the most frequent abnormality of HDL lipid 
composition and occurs in hypertriglyceridaemic states, associated with the decreased 
activity of lipoproteins lipase, the decreased activity of hepatic lipase, and/or the 
decreased activity of LCAT. All of these metabolic alterations are frequently observed in 
the acute phase and during inflammation (obesity and metabolic syndrome are 
characterised by a low grade inflammation). In addition, HDL triglycerides content can be 
raised as a consequence of elevated CETP-mediated triglycerides transfer from VLDL to 
HDL. Under such conditions, triglycerides typically replace cholesteryl esters in the HDL 
core, resulting in a low cholesteryl esters/triglycerides ratio and in a decrease in plasma 
HDL cholesterol levels; this is another feature of the acute phase response [36]. 
Interestingly, a similar elevation in HDL triglycerides, decrease in HDL cholesterol and 
increase in inflammatory markers is observed in the postprandial phase. Human acute 
phase HDL obtained from patients undergoing bypass surgery are enriched in 
triglycerides and depleted of cholesteryl esters. Acute phase HDL also contain elevated 
levels of non-esterified fatty acids, lysophosphatidylcholines and isoprostanes compared 
with normal HDL; in addition, cholesteryl esters levels are decreased. Similarly, HDL3 
from subjects with myocardial infarction are enriched in triacylglycerols (TAG) and 
depleted of phospholipids (PL). As a consequence of decreased LCAT activity, 
increased HDL concentrations of free cholesterol are frequently observed in inflammatory 
states; in addition, HDL free cholesterol is elevated in genetic LCAT deficiency [36]. 
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HDL metabolism is substantially altered in dyslipidaemic states, including 
hypertriglyceridaemia, hypercholesterolaemia, mixed dyslipidaemia and hypo- and 
hyperalphalipoproteinaemia, and also during infection and inflammation. As discussed 
above, hypertriglyceridaemia is characterised by decreased levels of HDL cholesterol 
and increased HDL triglycerides content due to the action of CETP. Such low HDL 
cholesterol dyslipidaemias associated with hypertriglyceridaemia are characteristic of 
metabolic diseases associated with elevated cardiovascular risk, such as type 2 diabetes 
and metabolic syndrome. Mechanisms leading to reduced plasma HDL cholesterol levels 
and HDL particle numbers in hypertriglyceridaemic states are as follows: 
1. small HDL particles, which result from the intravascular lipolysis of triglycerides-
enriched HDL, are cleared more rapidly from the circulation; 
2. triglycerides-enriched HDL are intrinsically more unstable in the circulation, with 
ApoA-I being loosely bound; 
3. lipolysis of triglycerides-enriched HDL lower HDL particle numbers by causing 
ApoA-I to be shed from HDL particles and cleared from the circulation; 
4. dysfunctional lipoprotein lipase or reduced lipoprotein lipase activity contributes 
to the lowering of HDL levels by reducing the availability of surface constituents 
of triglycerides-rich lipoproteins that sequester to the plasma pool of nascent 
HDL particles [37]. 
The cholesteryl esters/triglycerides ratio therefore represents a critical factor in 
determining HDL particle stability and plasma residence time; HDL possessing 
decreased cholesteryl esters/triglycerides ratios are less stable than normal particles 
[38]. Importantly, a decrease in circulating HDL cholesterol levels and an increase in 
triglycerides levels are typical components of the acute phase reaction [29]. HDL 
metabolism critically depends on the activity of CETP. In metabolic diseases such as type 
2 diabetes and metabolic syndrome, elevated CETP activity results in the increased 
transfer of cholesteryl esters from HDL to triglycerides-rich lipoproteins and in reciprocal 
triglycerides transfer, producing triglycerides-enriched HDL and decreasing HDL 
cholesterol levels. Conversely, CETP deficiency reduces the exchange of triglycerides 
and cholesteryl esters between HDL and triglycerides rich lipoproteins and elevates HDL 
cholesterol due to cholesteryl esters retention. As a consequence, increased CETP 
activity is thought to be proatherogenic in humans [39]. 
In hypercholesterolaemia, abnormalities of HDL metabolism include moderate decreases 
in plasma ApoA-I and HDL cholesterol levels. HDL heterogeneity and particle profile 
largely reflect abnormalities in HDL metabolism. In the atherogenic dyslipidaemias of 
metabolic syndrome and type 2 diabetes, circulating levels of large, cholesterol-rich HDL 
decrease in parallel with a decrease in HDL cholesterol. By contrast, levels of small, 
dense, cholesterol poor HDL particles and their content of ApoA-I are rarely reduced in 
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low HDL cholesterol dyslipidaemia [40]. In obesity and insulin resistance (frequent 
features of both metabolic syndrome and type 2 diabetes), plasma levels of large HDL 
decrease in parallel with those of HDL cholesterol, whereas levels of small HDL do not. 
As a result, metabolic syndrome, type 2 diabetes, obesity, and insulin resistance are all 
characterised by the prevalence of small, dense HDL [41]. 
Small, dense HDL also prevail in coronary heart disease patients. In male participants in 
the Framingham Offspring Study, subjects with coronary heart disease displayed higher 
levels of small particles [32]. Similarly, subjects with new cardiovascular events 
possessed higher levels of small HDL and lower levels of large HDL than subjects without 
such events in the Veterans Affairs HDL Intervention Trial (VA-HIT) study [42]. Coronary 
artery disease patients also displayed elevated levels of lipid-poor ApoA-I . The increase 
in small HDL and decrease in HDL of intermediate size, as measured by nuclear 
magnetic resonance, are associated with coronary artery disease severity in men 
admitted for diagnostic coronary arteriography [43,44]. Small HDL also prevail in 
peripheral arterial disease [45]. 
Alterations in HDL composition and metabolism, as occurring in dyslipidaemia and 
inflammation, are intimately associated with impaired biological activities. However, data 
on HDL cholesterol efflux capacity in atherogenic dyslipidaemia are conflicting. Some 
authors reported a diminished HDL capacity to deliver cholesteryl esters to hepatic cells 
through interaction with SR-BI as a result of HDL enrichment in triglycerides [46]. In 
contrast, others have reported normal cholesterol efflux capacity of serum from 
hypertriglyceridaemic subjects, which is an observation that can be related to normal 
contents of HDL phospholipids, a key determinant of HDL mediated efflux. Furthermore, 
HDL from hypertriglyceridaemic patients with low HDL cholesterol levels possess a 
normal capacity to extract cholesterol from smooth muscle cells. Consistent with these 
results, triglycerides-enriched HDL are not deficient in cholesterol efflux properties from 
cholesterol-loaded macrophages [47]. 
The intrinsic cholesterol efflux capacity of HDL is considerably impaired during 
inflammation. Cellular cholesterol efflux is largely mediated by ApoA-I-containing HDL 
particles; ApoA-I replacement by serum amyloid A can therefore have a significant 
impact on efflux. Enrichment of HDL with serum amyloid A (up to high serum amyloid A 
contents of 86% of total HDL protein) results in increased HDL binding to, decreased 
cholesterol efflux capacity from, and increased selective cholesteryl esters uptake by 
macrophages. Importantly, serum amyloid A selectively impairs the cholesterol efflux 
properties of small, dense HDL3 particles. Less pronounced enrichment of HDL with 
serum amyloid A in vivo (up to 27% of total HDL protein) does not influence cholesterol 
efflux but enhances HDL binding to macrophages [48]. 
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The presence of serum amyloid A increases both HDL affinity to and selective cholesteryl 
esters uptake by macrophages but reduces affinity to and cholesteryl esters uptake by 
hepatocytes. Decreased phospholipids contents in inflammatory HDL constitute another 
factor that contributes to deficient HDL cholesterol efflux properties. Together, these 
changes lead to a significant shift in the HDL-mediated cholesterol transport from 
hepatocytes toward macrophages under acute phase conditions. Biologically, such 
alterations may serve to redirect cholesterol to immune cells and to sites of injury and 
inflammation [49]. Abnormal lipid composition may also impair cholesterol efflux 
properties of HDL particles, as demonstrated by the diminished capacity of large 
cholesteryl esters-enriched HDL2 isolated from subjects with homozygous CETP 
deficiency to accept cholesterol from lipid-loaded mouse peritoneal macrophages. 
Normalisation of the lipid composition of such HDL, as a result of the transfer of excess 
cholesteryl esters to SR-BI overexpressing cells, improves HDL cholesterol efflux 
capacity [49]. 
Oxidative modification represents another factor involved in the impairment of HDL 
cholesterol efflux capacity. In vitro oxidation of ApoA-I by myeloperoxidase results in the 
selective inhibition of ABCA1 dependent cholesterol efflux from macrophages [50]. The 
cholesterol efflux capacity of ApoA-I may be also impaired as a consequence of non-
enzymatic glycosylation [28]. 
The central role of ApoA-I in HDL mediated cholesterol efflux is consistent with the 
deleterious role of ApoA-I mutations. However, not all mutations in ApoA-I lead to 
decreased cholesterol efflux capacity. ApoA-I Milano, a molecular variant of ApoA-I, 
displays potent capacity for cholesterol efflux. Carriers of ApoA-I Milano exhibit severe 
hypoalphalipoproteinaemia but are not at increased risk for premature CHD [51]. Finally, 
the capacity of HDL particles to extract cholesterol from peripheral cells may be impaired 
as a result of alterations in cellular HDL receptors, primarily ABCA1 [52]. 
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Oxidative stress and metabolic syndrome 
Accumulating evidence also demonstrates that damage to cellular components from 
reactive oxygen species (ROS) plays an integral role in the age-related deterioration of 
biochemical and physiologic processes and in the incidence of age-related disease. 
Oxidative stress, which is an excessive production of ROS outstripping endogenous 
antioxidant defence capacity, is implicated in oxidative damage to nucleic acids, 
proteins, carbohydrates, and lipids. From the molecular point of view, all of these 
alterations are derived directly or indirectly from the increase in low grade inflammation 
which involves, as a first effect, an increase in oxidative stress [6]. In recent years it has 
been assumed, with increasing accuracy, that the increase in levels of inflammation and 
oxidative stress represents the common thread of many seemingly different diseases 
such as diabetes and hyperglycaemia, hypertension, metabolic syndrome and obesity, 
depression, psychosis and attention-deficit disorder [53]. 
It is well known that mitochondria are the primary site for ROS generation as a by-product 
of aerobic metabolism, and that the accumulation of mitochondrial oxidative damage over 
time diminishes the cellular efficiency in energy production. ROS-induced damage is 
complex and frequently irreversible, and further impairs mitochondrial function, rendering 
them prone to further ROS generation. The cellular membranes are probably one of the 
first structures in a cell that can be been damaged by oxidative stress. The membrane 
fluidity is a consequence of the different molecules in the lipid bilayers. For example, the 
excessive presence of cholesterol and more saturated fat acids than unsaturated fat 
acids in phospholipids of membranes stiffens the bilayer structure of the membrane. Free 
radical can damage all cellular macromolecules, such as proteins, nucleic acids, and 
glycosaminoglycans, but above all affects polyunsaturated fat acids of the membrane 
phospholipids. This can give rise to two secondary types of reaction [54,55]: the 
formation of a cyclic lipid peroxide that can fragment during successive reactions and 
give rise to aliphatic chains containing two functional carbonyl groups, creating 
compounds such as malonyldialdehyde (MDA); or interaction between the lipid peroxyl 
radical and another lipid molecules with the formation of a stable lipid peroxide and a 
new lipid radical that can propagate further peroxidation reactions. Compounds of the 
MDA type are highly toxic because their carbonyl groups can react spontaneously with 
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the amino group of the membrane proteins and phospholipids forming stable covalent 
bounds. The formation of these bonds can cause serious damage to membranes and in 
general with regard to cellular function [56]. The cellular membrane holds 70% of all 
proteins in a cell and proteins represent the major holders of biological function. The 
peroxidation process reduces the freedom and possibility of movement of all proteins 
with a consequent loss of fluidity and hardening of the membrane. The diminished 
membrane fluidity encountered in these degenerative processes is the cause of 
secondary metabolic damage to cells. All of this results in the reduced capacity of the 
proteins to collide with the ligands with which they must interact in order to carry out their 
own functional and biological roles, such as enzymatic proteins interacting with their own 
specific substrate, the receptor proteins and their own specific hormone or 
neurotransmitter, the ion channels that permit electrolyte flow and the transmembrane 
carrier proteins for amino acids and glucose. 
One of most important examples of all this process involves the insulin receptor. This 
receptor is made like cone-shaped with the lower extremities outside the cell. With the 
hardening of the membrane, this receptor is pushed towards the interior of the cell. 
Usually, the insulin receptor protrudes out of the membrane of 1 Å, while, with the loss of 
fluidity of the membrane, the possibility to interact with insulin is reduced compared to the 
normal situation. In this way, oxidative stress and hardening of the membrane promotes 
insulin resistance. It is well-known that insulin acts as an important hormone controlling 
the production of energy and the synthesis of macromolecules such as proteins. A 
greater capacity to use energy is closely linked to the possibility of reducing oxidative 
damage in the cell. Accumulating evidence has suggested that insulin exerts important 
redox-regulating actions in various insulin-sensitive target organs, implying the systematic 
anti-oxidative role of insulin as a hormone [57]. These aspects are likely to demonstrate 
how the interaction between oxidative stress and metabolic syndrome is more profound 
and multifaceted than may appear at first glance. 
The role of oxidised LDL in atherogenesis 
LDL lipoproteins are composed of a core enriched in hydrophobic triglycerides and 
cholesterol ester molecules, enclosed by an envelope of phospholipids and unesterified 
cholesterol and apolipoprotein ApoB-100 [58]. The LDL lipoproteins are generally divided 
into three main subclasses based on density: LDL1 and LDL2 (density 1018-1030 g/mL), 
LDL3 (1030-1040 g/mL), LDL4 and LDL5 (1040-1065 g/mL). The small, dense LDL can 
more easily penetrate into the sub-endothelial space of the vascular wall and are more 
susceptible to oxidation [59]. A leading current hypothesis of the pathogenesis of 
atherosclerosis is that the release of oxygen free radicals from arterial endothelial cells 
and smooth muscle cells leads to the oxidation of LDL. Oxidative modification of LDL 
enhances its atherogenicity [60]. It has been demonstrated that the class of scavenger 
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receptors on macrophages takes up oxidised LDL, leading to the formation of foamy 
macrophages. Oxidised LDL also is chemotactic for monocytes and can cause 
endothelial damage. Oxidative damage of LDL is believed to occur primarily in the sub-
endothelial space of the vascular wall. During circulation, LDL enters and re-emerges 
from the sub-endothelial space. Increasing the time needed to remove fixed amounts of 
LDL from the circulation creates conditions that favour an increase in the number of LDL 
exposed to oxidative stress and the duration of exposure. Several components of LDL, 
including ApoB-100, phospholipids, cholesterol and unsaturated fatty acids, may be 
subject to oxidative stress [61]. Vitamin E is the principal fat soluble antioxidant that 
protects lipoproteins, but when it is consumed, the chain reaction continues and 
develops degradation products such as malondialdehyde [62]. 
Aldehydes can form Schiff bases with amino groups of lysine residues, creating cross-
links between lipids and proteins or between lipid molecules. These changes alter the 
protein fraction and reduce the affinity of LDL for its receptor, but increase the affinity for 
the scavenger receptor of macrophages, through which oxidised LDL exert their 
atherogenic action. Macrophages incorporate oxidised LDL, contributing to foam cell 
formation and playing a key role in cellular events that lead to the development of 
atherosclerotic lesions. The oxidation of lipoproteins in the plasma seems to occur with 
difficulty due to the presence of high concentrations of antioxidants and proteins that 
chelate metal [63]. 
It has been suggested that oxidised LDL are generated in the vessel wall and spread into 
the bloodstream after plaque rupture, increasing the permeability of plaques and leading 
to ischemic and inflammatory damage [64]. Several studies have found wide variation in 
the susceptibility of LDL from different individuals to oxidation ex vivo [58], although it has 
not yet been demonstrated convincingly that such variations are associated with the risk 
of atherosclerosis [63]. Vitamin E, the major antioxidant carried in LDL, may be one factor 
that influences the susceptibility of LDL to oxidation. Increasing the vitamin E content of 
lipoproteins in vitro or in vivo (by dietary supplementation) increases the lag phase for the 
initiation of LDL oxidation under certain conditions [63]. 
Other lipoprotein characteristics such as size and density also influence the extent of 
oxidation. Small-dense LDL is more susceptible to oxidation than large buoyant LDL, and 
increased levels of small-dense LDL are seen in various conditions that increase the risk 
of vascular disease, including diabetes, combined hyperlipidaemia, and familial 
dyslipidaemic hypertension. The increased susceptibility to oxidation may relate to these 
particles’ increased content of triglycerides, polyunsaturated fatty acids, and/or 
decreased vitamin E content [63]. 
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Figure 3- Macrophages incorporate oxidised LDL. In patients with hypercholesterolaemia, excess LDL 
infiltrates the artery and is retained in the intima. Oxidative and enzymatic modifications lead to the release 
of inflammatory lipids that induce endothelial cells to express leukocyte adhesion molecules. The modified 
LDL particles are taken up by scavenger receptors of macrophages, which evolve into foam cells. [8] 
The presence of an increased number of small, dense LDL particles is a constant feature 
of the dyslipidaemia of abdominal adiposity, as they are associated with insulin 
resistance, intra-abdominal fat, and hypertension [65-67]. LDL comprises a spectrum of 
particles that vary in size, density, chemical composition, and atherogenic potential. In 
conditions of elevated triglycerides, LDL particles become enriched in triglycerides and 
depleted in core cholesteryl esters. Hepatic lipase then acts to hydrolyse these 
triglyceride-rich LDL, forming smaller, denser LDL particles. The presence of small, 
dense cholesterol-depleted LDL particles is associated with an increased risk of 
myocardial infarction and worsened severity of coronary artery disease [68]. The Familial 
Atherosclerosis Treatment Study showed that the strongest predictor of coronary artery 
stenosis regression, induced by aggressive lipid lowering, was the increase in LDL 
buoyancy, not the change in LDL cholesterol level [69]. 
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Although the mechanisms underlying the association of small, dense LDL with increased 
risk of coronary artery disease are not clear, several hypotheses have been proposed. 
One explanation is that the presence of small, dense LDL particles is a marker of an 
atherogenic lipoprotein phenotype comprised of elevated triglycerides, reduced HDL, 
and elevated ApoB-100, which together increase coronary artery disease risk [70]. 
The protective role of HDL in atherogenesis 
The apparent importance of oxidative modification of low density lipoprotein in 
atherogenesis raises the question of how the oxidative modification of HDL might affect 
its cardioprotective actions [24]. HDL particles are the mainstay of atheroprotective 
defence mechanisms in humans. Reverse cholesterol transport from the peripheral 
tissues is the best known and salient activity. Moreover, such diverse mechanisms as 
antioxidant and anti-inflammatory functions via paraoxonase or apo A-I and A-II have 
been demonstrated. High-density lipoproteins also inhibit cytokine-induced expression of 
endothelial cell adhesion proteins, reduce superoxide production, and neutralise C-
reactive protein pro-inflammatory activity. HDL further possess inhibitory effects on 
thrombosis and apoptosis. Table 3 summarises the potential cardioprotective actions of 
HDL. However, under circumstances which are incompletely understood, 
atheroprotective activities of HDL may become deficient, via a process designated HDL 
dysfunctionality. 
Table 3 - Potential cardioprotective actions of HDL [24]. 
Actions References 
Reverse cholesterol transport [71] 
Inhibiting the formation and neutralising the effects of oxidised LDL [72-74] 
Inhibition of endothelial cell adhesion molecule expression [75] 
Binding bacterial endotoxin [76] 
Inhibiting LDL/oxidised LDL retention in the artery wall [77] 
Inhibiting platelet aggregation [78] 
Removal of lipid hydroperoxides [19] 
The level of high density lipoprotein (HDL) in plasma is an equally strong or stronger - but 
inverse - predictor of atherosclerotic vascular disease risk than LDL. It is held that each 1 
mg/dL increase in HDL cholesterol level is associated with a 2% to 3% decrease in the 
multiadjusted risk of coronary heart disease. Consequently, it was stated in the NCEP-
ATP III that HDL cholesterol concentrations in excess of 60 mg/dL counteract 1 risk factor 
[3]. The universality of this knowledge was recently challenged in some epidemiological 
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studies. In evaluating the significance for cardiovascular risk of HDL cholesterol levels, 
some aspects such as the size of HDL, the concentration of some apolipoproteins as 
ApoA-I, oxidation and glycation of HDL proteins and lipids have become highly important 
[23]. In patients with diabetes, glycation of HDL-associated enzymes and especially of 
ApoA-I depends on glucose concentration and is augmented in the presence of 
phospholipids. Deficient anti-inflammatory properties of HDL in type 2 diabetes mellitus 
have been ascribed to (a) HDL enrichment with conformational alterations of ApoA-I; (b) 
glycation of apolipoproteins and/or HDL-associated enzymes; and (c) oxidative 
modification of HDL lipids, apolipoproteins and/or enzymes [23,79]. 
Most studies looking at the relative susceptibility of lipoproteins to oxidation have found 
HDL to be more susceptible than LDL, with few exceptions. Despite their lower intrinsic 
antioxidant content, smaller HDL3 particles have been reported to protect LDL from 
oxidation more efficiently than HDL2 particles, possibly due to the preferential association 
of paraoxonase with HDL3. In addition, HDL containing ApoA-I as their only 
apolipoprotein may be more protective against LDL oxidation than HDL containing both 
ApoA-I and ApoA-II [80,81]. 
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Weight loss and metabolic syndrome 
Obesity and metabolic syndrome are important risk factors for coronary heart disease, 
ventricular dysfunction, congestive heart failure, stroke, and cardiac arrhythmias. Weight 
loss is probably one of the most important weapons against obesity, metabolic syndrome 
and an increased cardiovascular risk [82]. Intentional weight loss can improve or prevent 
many of the obesity-related risk factors for coronary heart disease (i.e., insulin resistance 
and type 2 diabetes mellitus, dyslipidaemia, hypertension and inflammation). Moreover, 
these metabolic benefits are often found after modest weight loss (5% of initial weight) 
and continue to improve in a monotonic fashion with increasing weight loss [83]. Fat loss 
can improve all features of the metabolic syndrome: 
1. Weight loss can prevent the development of new diabetes in high-risk persons 
who are overweight or obese. Lifestyle dietary and activity modifications, which 
resulted in modest (5%) weight loss, decrease from 4- to 6-years the cumulative 
incidence of diabetes by 50% in men and women who were overweight or 
obese and had impaired glucose tolerance [84]. 
2. Fat loss could in some cases decrease serum LDL cholesterol and triglyceride 
concentrations, whereas increases in serum HDL cholesterol typically are seen 
when weight loss is sustained. The beneficial effects on serum lipids are related 
to the percentage of weight lost, and regaining the lost weight leads to a relapse 
in serum concentrations. A sustained weight loss of 5% is needed to maintain a 
decrease in serum triglyceride concentrations [85]. 
3. Weight loss decreases both systolic and diastolic blood pressure in a dose-
dependent fashion; therefore, greater weight loss is generally associated with 
greater improvement in blood pressure [86]. 
4. Obesity is associated with an increase in circulating inflammatory markers, 
including C reactive protein (CRP) and cytokines (i.e., IL-6, IL-18 etc.). Adipose 
tissue itself is a likely source of these excess cytokines. The increase in 
inflammatory markers is associated with insulin resistance and is an important 
predictor of atherosclerotic events. Weight reduction decreases plasma CRP 
concentration. The decrease in CRP is directly related to the amount of weight 
loss, fat mass, and change in waist circumference [87].  
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Although fat loss could modify many cardiovascular disease (CVD) risk factors, it is not 
known whether weight reduction decreases CVD events or CVD mortality in obese 
people. Inflammation and oxidative stress are two of the main factors that must be 
considered in new studies about obesity and metabolic syndrome. One of the leading 
events that could connect vascular oxidative stress to atherosclerosis is the oxidative 
modification of lipoproteins. Oxidative damage to lipoproteins can not only make LDL 
atherogenic but can also reduce the anti-atherogenic properties of HDL [43,44]. While the 
effects on LDL have already been investigated the effects of oxidative stress on HDL 
have yet to be studied carefully. Moreover, the study of the different parts of lipoprotein, 
the core and the envelope, could give new information about the lipoproteins oxidisability 
and their oxidative damage. 
Lipoproteins and weight loss 
An interesting meta-analysis studied the effects of weight reduction by diets on plasma 
lipids and lipoproteins by analysing results from the 70 studies [85]. The importance of 
this meta-analysis is due to the fact that there is little clarity on the effectiveness of weight 
reduction on changes in plasma lipids and especially on the change of lipoproteins 
metabolism. Of primary interest is the fact that weight reduction is associated with a 
decrease of total cholesterol, LDL cholesterol, VLDL cholesterol and triglycerides when 
the levels of these lipids in blood are pathological. Overall correlations for the relationship 
between weight and change in various lipids and lipoproteins were also of primary 
interest. Weight reduction was associated with about 10% of the variance in change in 
total cholesterol. Each kilogram weight loss is associated with a 0.05 mmol/L decrease in 
total cholesterol. Mechanisms to explain how changes in body weight influence changes 
in lipids and lipoproteins results have not been clearly defined; however, body weight is 
the most important determinant of increased cholesterol synthesis that is often associated 
with obesity. Daily cholesterol production rate has been directly and significantly 
correlated with excess body weight [88]. An estimated cholesterol synthesis of about 20 
mg/dl for each kilogram body fat has been reported [89]. In addition to obesity being 
associated with hypercholesterolaemia, obesity is often associated with 
hypertriglyceridaemia, which is thought to result from either an increase in triglycerides 
production rate and impaired removal. Results from these meta-analyses indicate that 
each kilogram of weight loss is associated with a 0.015 mmol/L decrease in triglycerides.  
Lipoprotein lipase activity generally increases with weight loss, particularly once weight 
stabilises. However, during acute energy restriction, tissue concentrations of lipoprotein 
lipase have been reported to decrease by 50% to 80% [90]. Because of the decrease in 
lipoprotein lipase during active weight loss, triglycerides-rich lipoprotein synthesis in likely 
diminished and VLDL cholesterol catabolism impaired. Thus, the transfer of lipids to HDL 
cholesterol is limited, resulting in decreased HDL cholesterol during active weight loss. 
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When weight stabilised at a reduced level, lipoprotein lipase was reported to increase 
with an associated increased hydrolysis of VLDL cholesterol and transfer of lipids to HDL 
cholesterol. When subjects were at a reduced but stabilised weight, HDL cholesterol 
increased. Gender was significantly related to the change in HDL cholesterol and in 
triglycerides with weight loss; HDL cholesterol was expected to increase by 
approximately twice as much in males as in females. Triglycerides in males are expected 
to decrease by about 0.13 mmol/L more than in females. Males may show greater 
changes in triglycerides and in HDL cholesterol but the predicted changes for females 
were still beneficial. The age of the subjects is related to changes in LDL cholesterol with 
weight loss via other lipids or lipoproteins. There is an approximately four-fold difference 
in the predicted decrease in LDL cholesterol with weight reduction. Younger subjects are 
expected to decrease LDL cholesterol by 0.65 mmol/L, but older subjects are expected 
to decrease LDL cholesterol by only 0.21 mmol/L. Serum HDL cholesterol concentration 
have been reported in several population studies to be lower in cigarette smokers than in 
non-smokers; however, smoking has no effect on other lipids and lipoproteins. There is a 
negative association between cigarette smoking and body weight [91]. Alcohol is 
associated with increased triglycerides and HDL cholesterol concentration in the general 
population [92]. 
The weight reduction also affects the concentration of apolipoproteins and the 
concentration of enzymes connected to lipoproteins metabolism, consequently modifying 
the functions of the lipoproteins. In men with metabolic syndrome, weight loss of about 
10% of their initial weight decreases the concentration of ApoC-III by about one third and 
this reduction is associated with a decrease of ApoB-48 and triglycerides [93]. ApoC-III is 
presented in chylomicrons, in VLDL and in HDL and inhibits the lipoproteins lipase; 
consequently, its reduction stimulates the removal of triglycerides from the core of the 
HDL and from the other classes of lipoproteins with ApoC-III.  
Other works focus their attention on changes in HDL metabolism after weight loss. 
Previous studies have shown that hypercatabolism ApoA-I is the primary mechanism 
underlying the reduction of HDL cholesterol in obese people with insulin resistance [94]. 
In some cases, weight reduction in subjects with metabolic syndrome results in an 
increase in HDL cholesterol; this increase is attributed to a significant decrease of the 
catabolism rate of the ApoA-I with no change in the production rate of this apolipoprotein 
[95]. ApoA-I can be found only in HDL and activates LCAT, which catalyses the formation 
of cholesteryl ester using lecithin and cholesterol. This process results in the formation of 
HDL larger with a higher concentration of cholesteryl esters in the core and a reduction of 
free cholesterol on the amphipathic surface. HDL are divided into different 
subpopulations of particles with different size, density, electrophoretic mobility and 
composition also in lipids and apolipoproteins. This heterogeneity has important 
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implications for the function and properties of HDL. The infarction of cholesteryl esters in 
the core of HDL ends an increase in the size of HDL and their progressive instability. 
Studies with discoidal reconstituted high density lipoproteins suggest that HDL 
spontaneously increased the number of ApoA-I molecules from two to three [96] with a 
further stimulus to the action of LCAT. 
Studies on obese female subjects undergoing laparoscopic gastric banding show that 
weight decrease is also associated with a reduction in the plasma concentration of CEPT 
[97]. This enzyme is responsible for the transfer of triglycerides from VLDL and LDL to 
HDL and the reduction in concentration stops the massive transfer of triglycerides to HDL 
that is typical of the metabolic syndrome and dyslipidaemia.  
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Aim of the study 
A low-grade chronic inflammation can initiate and perpetuate an inflammatory cycle and 
pathophysiological signalling of inflammatory cells and adipocytes. Several adipokines 
have been suggested to act as a link between accumulated fat mass and insulin 
resistance [98]. The peripheral resistance to insulin is believed to play a central 
pathophysiological role in the metabolic syndrome, a condition that is characterised by 
dyslipidaemia (high triacylglycerols and low HDL-cholesterol), impaired carbohydrate 
metabolism and hypertension [99]. The anti-oxidative and anti-inflammatory action of HDL 
is now recognised as a major mechanism mediating its cardioprotective effect. One of the 
main events that could connect vascular oxidative stress to atherosclerosis is the 
oxidative modification of lipoproteins [100]. Oxidative damage to lipoproteins can not only 
make LDL atherogenic, but also can reduce the anti-atherogenic properties of HDL 
[43,44]. As previously described, metabolic syndrome can exacerbate lipoprotein 
oxidation and dysfunction [101]. Lipid peroxidation can occur both in the envelope and 
the core of plasma lipoproteins. The possibility of following the lipid peroxidation of the 
individual regions of LDL and HDL could lead to more detailed information on the 
modifications that are the basis of the increased risk of cardiovascular diseases observed 
in obesity and metabolic syndrome.  
A previous study [102] that aimed to investigate the composition, oxidisability and fluidity 
of the hydrophobic core and surrounding amphipathic envelope of HDL in two adult male 
groups with the aim of providing more detailed information on the features of HDL in 
mixed dyslipidaemia patients, has already proven a change in the percentage 
composition of HDL that are enriched in triglycerides with a parallel increase oxidisability, 
with a reduction of the lag-time and an increase in the velocity of propagation of 
peroxidation. 
Based on these data, I performed the following study, in which I investigated the change 
in susceptibility to peroxidation of the hydrophobic core and the surrounding envelope of 
LDL and HDL in obese males (BMI between 25 and 40 Kg/m2) with metabolic syndrome 
[15]. The most ambitious aim of this study is to evaluate the change of these parameters 
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after weight decreases of at least 5% of initial weight following a hypocaloric diet. The 
lipid composition of all classes of lipoproteins was also measured as it represents an 
important area of study for understanding the biochemical basis of changes in 
oxidisability. 
A study of the correlations between the state of susceptibility to peroxidation of 
lipoproteins, the chemical composition of the different lipoprotein classes and the most 
common clinical parameters has the aim of investigating the possible mechanisms of 
changes in these parameters and the possible correlations with medical practice. 
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Materials and methods 
Materials 
Analytical grade chemicals and solvents were used with double-distilled water. β-(Pyren-
1-yl) decanoyl γ-palmitoyl L-α phosphatidylcholine (PyrPC), cholesteryl (pyren-1-yl) 
hexanoate (PyrCE), 2,2′-azobis(2-methylpropionamidine) dihydrochloride (AAPH), were 
from Sigma Aldrich (Milan, Italy). The kits for the determination of cholesterol and 
triglycerides were from Scalvo (Siena, Italy). Organic solvents were purchased from 
Merck (Merck Italy, Milan, Italy). 
Subjects 
The recruitment took place at Istituti Clinici di Perfezionamento and at Ospedale Luigi 
Sacco, Milan. To be included in the study, patients had to have the following 
characteristics: age between 18 and 55 years (but not undergoing menopause in 
women), BMI between 25 and 40 kg/m2, absence of major diseases, lack of drug 
therapies in place that are able to influence lipid profile (e.g. oestroprogestinics, statins, 
oral hypoglycaemic agents, treatment with thyroid hormone synthesis), lack of use of 
antioxidant supplements, no smoking and alcohol consumption of less than 25 g/day. 
The recruited subjects underwent a medical visit. Blood pressure and physical data 
(weight, height, waist circumference, and hip circumference) were determined during a 
complete clinical examination. Family history information was collected for overweight 
and obesity, dyslipidaemia, diabetes and cardiovascular disease. Physiological history 
was assessed, investigating the level of physical activity, the presence of cigarette 
smoking and consumption of alcoholic beverages and the characteristics of the 
menstrual cycle or the possible presence of menopause in women. Proximate and remote 
medical history were assessed, investigating the presence of any major diseases or the 
presence of ongoing drug therapy or antioxidant supplementation. Dietary food recall of 
one day and survey of food weekly frequency consumption was collected. 
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Clinical chemistry parameters (complete blood count, total cholesterol, HDL cholesterol, 
triglycerides, blood glucose, insulin, creatinine, AST, ALT, CRP, TSH, uric acid) were 
determined under strictly standardised conditions with dedicated commercial kits. To 
achieve the goal of weight loss of at least 5% of the initial weight, a second medical visit 
was performed. Blood pressure and physical data were determined on a second 
occasion, as were clinical chemistry parameters. 
The study was approved by the ethics committee of the Istituti Clinici di Perfezionamento 
and Ospedale Luigi Sacco and was carried out in accordance with the principles of the 
Declaration of Helsinki as revised in 2000. Subjects gave their written consent to the 
study. 
Diet intervention 
The diet intervention was aimed at achieving weight loss of at least 5% by focusing on 
reduced caloric intake. All subjects followed the same type of diet. All specific 
intervention strategies included a calorie goal of 1400 to 2000 kcal per day (with <30% of 
calories from fat and >15% from protein) according to clinical evaluation. The program 
included both group and individual counselling sessions with a dietician. Table 1 shows 
the average nutritional analysis of diets. 
Table 1 - Average nutritional analysis of diets administered to patients with the objective of reducing the 
weight of the 5%. Calorie goal of 1400 to 2000 kcal per day. Results were reported as mean ± Standard 
Error of the Mean (SEM). 
Average nutritional analysis 
Proteins                    
(% of total calories) 18 ± 0.3 
Saturated fats           
(g) 13 ± 1.5 
Ca                     
(mg) 736 ± 84 
Lipids                       
(% of total calories) 28 ± 1.9 
Polyunsaturated fats   
(g) 6 ± 0.9 
Fe                      
(mg) 15 ± 0.9 
Carbohydrates            
(% of total calories) 54 ± 2.2 
Fibres                        
(g) 26 ± 2.5 
Na                     
(mg) 2193 ± 262 
Alcohol                     
(% of total calories) 0 
Cholesterol            
(mg) 191 ± 18 
K                        
(mg) 3514 ± 226  
  Vitamin E               (mg) 10 ± 0.7 
P                        
(mg) 1051 ±133 
  Folate                     (µg) 295 ± 15  
Zn                     
(mg) 10 ± 0.7 
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Blood collection and separation 
Both at the initial time and to achieve the goal of weight loss, blood samples were 
obtained after overnight fasting by venipuncture and were collected in heparinised 
Vacutainer tubes. The sample was transported in a refrigerated box to our laboratories 
where it was processed for the separation of plasma. Each stage of the separation was 
carried out whilst maintaining the sample at a temperature of approximately 4°C using a 
bath of water and ice. Plasma was separated by centrifugation at 3000 rpm at 4°C before 
being aliquoted and stored at -80°C until use. 
Plasma lipoproteins separation 
Lipoproteins were isolated from plasma by ultracentrifugation using a multistep 
discontinuous density gradient of KBr, with an adaptation of procedure 16 in ref. [103] to 
“Optima Max” tabletop ultracentrifuge (Beckman Coulter). To remove albumin completely, 
the HDL fraction (density, 1.063–1.210 g/ml) was subjected to a second centrifugation 
(procedure 15 in ref. [103]). After separation, lipoproteins were dialysed against 10 mM 
phosphate buffered saline pH 7.4 (10 mM sodium phosphate buffer pH 7.4 containing 
154 mM NaCl) at 4°C in the dark for 12 hours in order to eliminate KBr. Isolated and 
dialysed lipoproteins were stored. 
Lipoprotein characterisation 
The proteins concentration of each lipoprotein fraction was determined with the Lowry 
method using bovine serum albumin as standard [104]. Total lipids were extracted from 
each lipoprotein fraction following the Folch procedure [105]. The phospholipid content 
was determined according to Bartlett [106]; cholesterol and triglycerides were 
determined using a commercial reagent kit from Scalvo (Siena, Italy) [107,108]. 
Labelling of lipoproteins with fluorescent probes 
We incorporated β-(pyren-1-yl) decanoyl γ-palmitoyl L-α phosphatidylcholine (PyrPC) or 
cholesteryl (pyren-1-yl) hexanoate (PyrCE) in their monomeric forms, as previously 
described [102,109], into HDL and LDL to measure the oxidisability of the hydrophobic 
core and surrounding amphipathic envelope. To label the hydrophobic core of this 
lipoproteins, plasma was incubated with PyrCE (10 nmol/mL) mixed with egg 
phosphatidylcholine (1:10 mol:mol). PyrPC (5 nmol/mL) was used to label the lipoproteins 
envelope. The probes were suspended with chloroform methanol (2:1), and then 
evaporated under a nitrogen stream. The probes were dissolved with a 10 mM phosphate 
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buffered saline pH 7.4 (10 mM sodium phosphate buffer pH 7.4 containing 154 mM NaCl) 
and then added to plasma. Plasma was incubated with probes for one hour at room 
temperature in the dark before the isolation of lipoproteins as described above. 
Ohnishi et al. [109] showed that pyrene-labelled lipids are incorporated into lipoproteins 
in the positions where the corresponding non-pyrene lipids were located with respect to 
the distribution between the hydrophobic core and the amphipathic surface, without 
introducing drastic changes in the chemical compositions of lipoproteins. 
Lipoprotein peroxidation 
The two different pyrene derivatives were used to follow lipid peroxidation in low and high 
density lipoproteins. We used the fluorescence decrease of PyrCE to monitor the lipid 
peroxidation in the hydrophobic core of LDL and HDL, and that of the amphipathic 
probes PyrPC, to follow lipid peroxidation in the envelope of both lipoproteins. Labelled 
lipoproteins were resuspended (100 μg protein/mL) in phosphate-buffered saline pH 7.4, 
and peroxidised at 37°C by incubation with AAPH 1 mM. The AAPH is a water soluble 
compound which decomposes at 37°C generating a continuous flow of free radicals. 
The oxidation of labelled LDL and HDL was monitored by the decrease in the pyrene 
fluorescence emission intensity at 378 nm (excitation λ=343 nm). This decrease was 
expressed as:  
((Fo-Ft)/Fo) × 100 
where Fo represents the fluorescence intensity at zero time of peroxidation and Ft the 
residual fluorescence for ever experimental time. The kinetics is expressed by a 
sigmoidal curve that can be divided into an initial latency phase, and a second 
propagation phase followed by a termination phase. The kinetic profile of these curves 
allows the evaluation of at least two indices and offers a good description of the process 
of plasma peroxidation. These indices are: the maximal rate of oxidation, which can be 
calculated from the slope of the fluorescence curve during the propagation phase, and 
the lag-time, expressed in minutes and calculated from the intersection of the linear 
regression of the propagation phase tangent with that of the lag-phase. The length of the 
lag phase (lag-time) and the velocity of the reaction in the propagation phase (slope) of 
peroxidation kinetics were calculated and used as indices of lipoprotein oxidisability 
[110]. 
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Statistics 
Data are expressed as mean ± SEM. The average values in subjects after and before 
weight lost were compared. The differences between the two times were analysed 
statistically using the Wilcoxon test for matched pairs [111] and were considered 
significant for p values ≤ 0.05. Correlations between variables were calculated by 
Spearman Rank Correlation Coefficient [112]. All statistical analyses were performed 
using GraphPad Instat software (GraphPad Software, V 2.02). 
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Results 
Subjects 
For this study, we enrolled 106 patients, of which 44 were obese (males 27 females 17) 
and 62 were obese with metabolic syndrome (males 32 females 30), defined according to 
The National Cholesterol Education Program’s Adult Treatment Panel III definition (ATP III) 
[3]. At the end of my PhD course, 23 subjects had lost more than 5% of their initial weight, 
of which 3 were obese (2 males and 1 female) and 20 were obese with metabolic 
syndrome (16 males and 4 females). The following results refer to 16 males obese with 
metabolic syndrome that lost more than 5% of their initial weight. Table 3 reports the 
features of the subjects at initial time and after weight loss. There were differences in 
blood pressure (both systolic and diastolic), waist and hip circumference. waist/hip ratio, 
glycaemia, insulin, HOMA-IR and ALT, regardless of whether there were differences in 
complete blood count, total cholesterol, HDL cholesterol, triglycerides, creatinine, AST, 
CRP, TSH and uric acid. There was a significant reduction of weight with an average 
percentage decrease of 8.28 ± 0.69%. There was a significant reduction in systolic and 
diastolic blood pressure after weight loss and a significant decrease in waist 
circumference, hip circumference and waist/hip ratio. Also, glucose metabolism bettered 
with a reduction of glycaemia, insulin and HOMA-IR after weight loss. Lipids 
concentration in blood did not change significantly although there was a trend of 
reduction of triglycerides which decreased from 135.1 mg/dl to 119.5 mg/dl. Total 
cholesterol, HDL cholesterol, total cholesterol/HDL cholesterol ratio, as well as HDL 
cholesterol/triglycerides ratio, did not change with weight reduction in this population. The 
diagnosis of metabolic syndrome according to NCEP-ATP III criteria was based on 5 
standards and after weight loss, the subjects examined were improved in at least 3 
criteria with better blood pressure, better glucose metabolism and a reduction of waist 
circumference. It is noteworthy that the lipaemia fell within the normal range even at the 
initial time of study. ALT is considered a surrogate marker of liver injury [113] and the 
significant decrease of ALT levels after weight loss was considered indicative of a 
reduction in hepatic inflammation. Finally, there was a reduction of CRP, with values that 
were halved from 0.40 mg/dl to 0.21 mg/dl, although this change did not quite reach 
statistical significance. 
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Table 3 - Anthropometric characteristics, blood pressure and clinical blood parameters of subjects before 
and after weight loss. 
 
 Before weight lost After weight lost Wilcoxon test 
 Mean SEM Mean SEM p 
Weight (kg) 100.8 2.4 92.3 2.0 < 0.0001 
BMI (kg/m2) 33.83 0.93 30.99 0.78 < 0.0001 
 Systolic blood pressure (mmHg) 142 4 127 3 0.0017 
Diastolic blood pressure (mmHg) 90 2 78 2 0.0007 
Waist circumference (cm) 113.8 2.4 106.1 1.7 < 0.0001 
Hip circumference (cm) 112.6 2.5 108.6 1.9 0.0017 
Waist/hip ratio 1.01 0.01 0.98 0.01 0.0001 
Glycaemia (mg/dl) 106.9 5.1 98.2 4.2 0.0085 
Insulin (μU/l) 14.71 3.92 8.47 1.18 0.0098 
HOMA-IR 3.83 1.04 2.03 0.32 0.0049 
Total cholesterol (mg/dl) 195.0 6.6 189.8 7.3 0.2744 
HDL cholesterol (mg/dl) 47.1 3.0 47.9 3.6 0.5830 
LDL cholesterol (mg/dl)* 119.2 6.0 118.1 5.3 0.8999 
Total cholesterol/ HDL cholesterol ratio 4.36 0.24 4.21 0.25 0.1439 
Triglycerides (mg/dl) 135.1 15.6 119.5 12.9 0.1514 
HDL cholesterol/triglycerides ratio 0.49 0.063 0.51 0.068 0.9152 
Uric acid (mg/dl) 6.58 0.34 6.50 0.38 0.7615 
Creatinine (mg/dl) 0.97 0.04 0.96 0.06 0.9102 
AST (U/l) 29 2 29 2 0.8394 
ALT (U/l) 43 4 32 3 0.0007 
CRP (mg/l) 0.40 0.11 0.21 0.07 0.0781 
Leukocytes (103/ml) 6.8 0.35 6.4 0.28 0.3203 
Erythrocytes (106/ml) 5.2 0.16 5.1 0.20 0.0830 
 
SEM = Standard Error of the Mean, BMI = Body Mass Index, HOMA-IR = Homeostatic Model Assessment - 
Insulin Resistance, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, CRP = C Reactive 
Protein. 
* Calculated by Friedewald formula. 
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Lipoproteins susceptibility to peroxidation 
Table 4 shows the results for lipoproteins peroxidation: lag-time results are expressed in 
minutes while slope measures are expressed as percentage decrease for one minute. 
The hydrophobic core of LDL showed a reduction in lag-time after weight loss (from 17.8 
minutes to 8.5 minutes) regardless of whether the same region of HDL showed a greater 
resistance to peroxidation after weight loss (lag-time from 3.9 minutes to 8 minutes). 
There were also differences in slope after weight reduction that increased in the 
hydrophobic core of LDL and decreased in the HDL core (from 0.82% decrease/min to 
1.16% decrease/min and from 1.74% decrease/min to 1.42% decrease/min, 
respectively). The parameters indicative of susceptibility to peroxidation of the 
surrounding amphipathic envelope of lipoproteins did not statistically significantly differ 
after and before weight loss. 
Table 4 – Oxidisability of the hydrophobic core and amphipathic surface of HDL and LDL. 
 
 
Before weight lost After weight lost Wilcoxon test 
 Mean SEM Mean SEM p 
HDL hydrophobic core        
lag-time (min) 3.9 0.7 8.0 1.1 < 0.0001 
HDL hydrophobic core     
slope (% decrease/min) 1.74 0.18 1.42 0.11 < 0.0001 
HDL amphipathic surface    
lag-time (min) 7.4 1.4 7.5 1.7 0.4637 
HDL amphipathic surface  
slope (% decrease/min) 1.67 0.11 1.80 0.20 0.6685 
LDL hydrophobic core         
lag-time (min) 17.8 1.8 8.5 1.3 < 0.0001 
LDL hydrophobic core      
slope (% decrease/min) 0.82 0.06 1.16 0.09 0.0006 
LDL amphipathic surface    
lag-time (min) 17.5 1.9 13.9 2.7 0.2769 
LDL amphipathic surface 
slope (% decrease/min) 0.87 0.08 0.92 0.09 0.9799 
 
SEM = Standard Error of the Mean, VLDL = Very Low Density Lipoproteins, LDL = Low Density 
Lipoproteins, HDL = High Density Lipoproteins. 
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Figure 4 - Oxidisability of the hydrophobic core and amphipathic surface of HDL. These histograms 
graphically show the results for the lag-time and slope as indices of peroxidation of HDL. The top line 
shows the data relative to the hydrophobic core, while the lower line shows the data of the amphipathic 
surface. 
 
 
In confirmation of the interdependence of data, there are correlations between the 
parameters of HDL and LDL peroxidation in different regions themselves, as well as 
between them and the data of chemical composition of lipoprotein. There is an inverse 
correlation between lag-time of the hydrophobic core of HDL and LDL and the velocity of 
propagation of the peroxidation (slope) in the same region of lipoproteins (R=-0.3399, 
p=0.0208, 95% CI -0.5795 to -0.0461; R=-0.3456, p=0.0186, 95% CI -0.5838 to 0.05262 
respectively). There was a strong positive correlation between lag-time of core and lag-
time of amphipathic envelope both in HDL and LDL (for HDL R=0.4437, p=0.002, 95% CI 
0.1675 to 0.6554 and for LDL R= 0.752, p<0.0001, 95% CI 0.5849 to 0.8579). 
Interestingly, lag-time of the envelope of HDL also correlated positively with the lag-time 
of both regions of LDL (hydrophobic core R=0.3661, p=0.0123, 95% CI 0.07601 to 
0.5991 and amphipathic envelope R=0.4318, p=0.0027, 95% CI 0.1531 to 0.6469). 
p < 0.0001 
p < 0.0001 
  45 
Figure 5 - Oxidisability of the hydrophobic core and amphipathic surface of LDL. These histograms 
graphically show the results about the lag-time and slope as indices of peroxidation of LDL. The top line 
shows the data relative to the hydrophobic core, while the lower line shows the data of the amphipathic 
surface. 
 
 
There were correlations between anthropometric and clinical blood parameters and 
indicators of peroxidation and chemical composition of lipoproteins, which will be 
summarised below. BMI was strictly inversely correlated with lag-time of the hydrophobic 
core and surrounding envelope of HDL (R=-0.5738, p<0.0001, 95%CI -0.7447 to -0.3323 
and R=-0.5165, p=0.0002, 95% CI -0.7061 to -0.2578, respectively), whereas it was 
positively correlated with the slope of HDL core (R=0.3142, p=0.0335, 95% CI 0.1735 to 
0.5601). BMI was also positively correlated with the concentration of proteins, both in 
VLDL (R=0.3417, p=0.0201, 95% CI 0.04815 to 0.5809) and in LDL (R=0.4275, p=0.003, 
95% CI 0.1479 to 0.6438), and with the percentage of triglycerides in HDL (R=0.4653, 
p=0.0011, 95% CI 0.1938 to 0.6706), whereas it was inversely correlated with the 
percentage of cholesterol in HDL (R=-0.4397, p=0.0022. 95% CI -0.6525 to -0.1626). 
p < 0.0001 
p = 0.0006 
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The value of waist circumference as well as that of hip circumference were inversely 
correlated to lag-time both in the core and in the envelope of HDL (for waist 
circumference R=-0.3743, p=0.0104, 95% CI -0.6052 to -0.08543 and R=-0.3743, 
p=0.0104, 95% CI -0.6052 to -0.08543, respectively, and for hip circumference R=-
0.3083, p=0.0371, 95% CI -0.5556 to -0.01083 and R=-0.4669, p=0.0011, 95% CI -
0.6718 to -0.1958, respectively). 
There were a positive correlation between concentration in plasma of HDL cholesterol 
and slope of HDL core (R=0.4606, p=0.0013, 95% CI 0.1879 to 0.6673) and an inversely 
correlation between plasma HDL cholesterol and slope of core and envelope of LDL (R=-
0.292, p=0.0489, 95% CI -0.5431 to 0.007006 and R=-0.4214, p=0.0035, 95% CI -0.6394 
to -0.1406 respectively). 
The total cholesterol/HDL cholesterol ratio was inversely correlated to concentration of 
protein in HDL (R=-0.6127, p< 0.0001, 95% CI -0.7703 to -0.3846). The HDL 
cholesterol/triglycerides ratio was positively correlated to velocity of the reaction of 
peroxidation in core of HDL (R=0.3311, p=0.0246, 95% CI 0.03629 to 0.573) and 
inversely correlated to the slope of both the core and envelope of LDL (R=-0.3478, 
p=0.0179, 95% CI -0.5854 to -0.05504 and R=-0.3703, p=0.0113, 95% CI -0.6022 to -
0.0808, respectively). There was also a negative correlation of this ratio with proteins 
concentration in VLDL (R=-0.6739, p< 0.0001, 95% CI -0.8095 and -0.47) and a positive 
correlation with proteins concentration in HDL (R=0.4189, p=0.0038, 95% CI 0.1376 to 
0.6376). 
Lipoproteins composition 
Data show statistically significant differences before and after weight lost in lipoprotein 
compositions. Table 5 shows the chemical composition of lipoproteins: the results for 
lipids are expressed in ratio weight/weight and in nmoles/ml, while the results for proteins 
are expressed in µg/ml. Usually, the lipid composition of lipoproteins is expressed in 
weight/weight ratio to better understand the interaction between the different classes of 
lipids; generally, this is the common way to show results in the literature and in 
biochemical books. I think that relative values and absolute values have to be compared 
and although ratio weight/weight remains the standard way to express these data, the 
evaluation of changes in the number of moles offers a different perspective of reasoning. 
LDL show a higher percentage content of triacylglycerols (TAG) after weight loss (from an 
initial 20% to a 26% after weight reduction), whereas HDL reduce the percentage content 
of TAG (from 24% to 20%). Proteins concentration and the percentages of cholesterol 
and of phospholipids (PL) decrease after weight loss in LDL, regardless of an increase in 
HDL. There were no differences in VLDL composition before and after weight reduction. 
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Table 5 - Chemical composition of lipoproteins at initial time and after weight loss, divided into different 
classes. The results for lipids are expressed in weight/weight ratio of total lipids and in nmoles/ml, while the 
results for proteins are expressed in µg/ml. Molecular mass for cholesterol = 386.675 kg/moles. Average 
molecular mass for triglycerides = 869.6 kg/moles. The total phospholipid concentration of lipid extracts 
was determined by phosphorous assay. The phospholipids/proteins ratio is expressed in weight/weight 
ratio. 
 
  Before weight 
lost 
After weight 
lost 
Wilcoxon 
test 
  Mean SEM Mean SEM p 
Proteins VLDL (µg/ml) 853 109 798 99 0.6322 
Cholesterol VLDL (% w/w) 32 1.43 30 1.06 0.1040 
 (nmoles/ml) 989 140 842 119 0.4332 
Triglycerides VLDL (% w/w) 52 1.40 53 0.96 0.9032 
 (nmoles/ml) 700 99 671 98 0.7820 
Phospholipids VLDL (% w/w) 16 0.19 17 0.43 0.1016 
 (nmoles/ml) 236 32 235 31 0.9515 
Phospholipids/proteins ratio (w/w) 24.8 3.74 24.9 3.05 0.8603 
Proteins LDL (µg/ml) 1281 88 1135 64 0.0443 
Cholesterol LDL (% w/w) 46,3 0.60 43 0.62 0.0012 
 (nmoles/ml)  2617 155 2638 155 0.8469 
Triglycerides LDL (% w/w) 20,4 0.59 26 0.46 < 0.0001 
 (nmoles/ml) 512 30 699 43 0.0003 
Phospholipids LDL (% w/w) 34,0 0.24 31 0.43 0.0017 
 (nmoles/ml) 930 49 942 51 0.7820 
Phospholipids/proteins ratio (w/w) 59.3 4.64 66.2 4.38 0.4037 
Proteins HDL (µg/ml) 876 62 1044 59 0.0010 
Cholesterol HDL (% w/w) 37 0.49 39 0.46 0.0005 
 (nmoles/ml) 1211 69 1151 89 0.8209 
Triglycerides HDL (% w/w) 24 0.35 20 0.34 < 0.0001 
 (nmoles/ml) 332 22 262 21 0.0125 
Phospholipids HDL (% w/w) 39 0.45 41 0.42 0.0046 
 (nmoles/ml) 609 38 608 45 0.8209 
Phospholipids/proteins ratio (w/w) 55.7 3.64 46.3 3.60 0,1754 
 
SEM = Standard Error of the Mean, VLDL = Very Low Density Lipoprotein, LDL = Low Density Lipoprotein, 
HDL = High Density Lipoprotein. 
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Figure 6 - Lipid composition of the different classes of lipoprotein at initial time and after weight loss. The 
percentages of phospholipids are shown in yellow, the percentages of triglycerides are shown in green and 
the percentages of cholesterol are shown in blue. All data are expressed in weight/weight ratio on total 
lipids. 
 
VLDL = Very Low Density Lipoproteins, LDL = Low Density Lipoproteins, HDL = High Density Lipoproteins. 
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To better investigate the molecular reasons for the changes in parameters of peroxidation 
in lipoproteins, the correlation between lag-time and slope in the different areas of HDL 
and LDL and the lipoprotein chemical composition was studied. The lag-time of the 
hydrophobic core of HDL was positively correlated with the percentage of cholesterol in 
HDL, and it was inversely correlated with the percentage of triglycerides in HDL 
(R=0.4805, p=0.0007, 95% CI 0.2126 to 0.6813 and R=-0.6378, p<0.0001, 95% CI -
0.7865 to -0.4191 respectively). To confirm this, a positive correlation was identified 
between the change after weight loss in the lag-time of the HDL core and the variation of 
the percentage of cholesterol in HDL, along with a negative correlation between the 
change of lag-time in the same region of HDL and the change of percentage of 
triglycerides in HDL (R=0.6084, p=0.0021, 95% CI 0.2496 to 0.8203 and R=-0.4166, 
p=0.048, 95% CI -0.7138 to -0.007752 respectively). There was a positive correlation 
between the velocity of propagation of peroxidation in core of HDL (slope) and the 
percentage of triglycerides in HDL, irrespective of whether there was an inverse 
correlation between the slope of HDL core and percentage of phospholipids in HDL 
(respectively R=0.3659, p=0.0124, 95% CI 0.07572 to 0.5989 and R=-0.3339, p=0.0233, 
95% CI -0.5750 to -0.03936). To complete the picture of the correlation there was a 
negative correlation between the lag time in the hydrophobic core of HDL and the 
phospholipids/proteins ratio in HDL (R=-0.4537, p=0.0091, 95% CI -0.6984 to -0.1140). 
With regard to LDL, lag-time of the hydrophobic core was positively correlated with the 
percentage of cholesterol in LDL and inversely correlated with the percentage of 
triglycerides in LDL (R=0.5241, p=0.0002, 95% CI 0.2675 to 0.7113 and R=-0.5074, 
p=0.0003, 95% CI -0.6999 to -0.2463, respectively). The slope in the core of LDL was 
inversely correlated with the percentage of cholesterol in LDL and positively correlated 
with the percentage of triglycerides in LDL (for cholesterol R=-0.3849, p=0.0083, 95% CI 
-0.6129 to 0.09762 and for triglycerides R= 0.5063, p=0.0003, 95%CI 0.2448 to 0.6991). 
There was a positive correlation between the lag-time of LDL amphipathic surface and 
the percentage of cholesterol in LDL and a negative correlation with the percentage of 
triglycerides in LDL (R=0.4086, p=0.0048, 95% CI 0.1254 to 0.6302 and R=-0.3318, 
p=0.0243, 95% CI -0.5735 to -0.03705, respectively). Finally, there was a negative 
correlation between the change in the percentage of triglycerides in LDL after weight loss 
and the variation of the percentage of triglycerides in HDL (R=-0.4536, p=0.0297, 95% CI 
-0.7355 to -0.03782). 
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Discussion 
The susceptibility to peroxidation of the core of LDL and HDL appears to be especially 
influenced by their content of triglycerides. Consequently, the transfer of triglycerides 
from HDL to LDL results in an improvement of HDL and in a worsening of LDL in relation 
to the oxidisability. There was a strong reduction in the percentage of TAG in HDL from 
24% to 20% (also supported by a reduction of absolute value of TAG expressed in 
nmol/ml). The change in chemical composition also justifies the change in susceptibility 
to peroxidation of HDL: resistance to the initial peroxidation increases while the 
propagation rate of peroxidation processes decreases in the core of HDL. This change in 
oxidisability is probably the result of the reduction of TAG in the core of HDL. This 
hypothesis is supported by an inverse correlation between the percentage of TAG in HDL 
and the lag-time in the core of HDL and also by a positive correlation between the 
percentage of cholesterol in HDL against lag-time in the HDL core. Further confirmation 
was provided by the fact that there is a positive correlation between the change in lag-
time of the HDL core and the variation in the percentage of cholesterol in HDL and a 
negative correlation with the change of percentage of TAG. Also, the chemical 
composition of LDL changed dramatically and there is a strong increase of TAG from 
20% to 26% (also supported by an increase of absolute value of TAG expressed in 
nmol/ml). Studying LDL after weight loss, a reduction in the percentage of cholesterol 
(from 46% to 43%) and phospholipids (from 33% to 31%) is also evident. The LDL 
enriched in TAG and with less cholesterol (probably due to less cholesteryl esters) are 
probably smaller and denser, increasing the cardiovascular risk [70]. Although the 
mechanisms underlying the association of small, dense LDL with increased risk of 
coronary artery disease are not clear, several hypotheses have been proposed. 
Mechanistically, small, dense LDL particles enter the arterial wall more easily [114], bind 
to arterial wall proteoglycans more avidly [115], and are highly susceptible to oxidative 
modification [116], leading to macrophage uptake, all of which may contribute to 
increased atherogenesis. The major oxidisability of LDL is shown by the dramatic 
reduction of lag-time and by the increase in the velocity of propagation of the reaction of 
lipid peroxidation in the core of LDL after weight loss. When studying lipoproteins out of 
plasma and without the protection of plasma antioxidant molecules, our experimental 
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model mimics the condition of lipoproteins in extravasal matrix. Similarly to in vivo 
expectations, lipoprotein oxidation in our in vitro model was induced by a flux of aqueous 
peroxyl radicals derived from the thermal decomposition of AAPH, which first comes into 
contact with different molecular species on the lipoproteins’ surface like PL, cholesterol 
and proteins. Since the PL oxidisability to this radical species is known to be higher than 
that of cholesterol and apolipoproteins, it is reasonable to suppose that the 
polyunsaturated fatty acids of PL are the first substrates that start to be peroxidised, thus 
promoting the initial lipid peroxide formation in the lipoproteins surface region. The 
peroxidised lipids so formed on the surface can then propagate the peroxidation into the 
core of the lipoproteins. These peroxides probably propagate more easily in the core of 
lipoproteins because there is a higher fluidity, which is attributed to the fluidising effect 
arising from the increased presence of TAG. This effect is also probably due to the fact 
that TAG are a more oxidisable substrate than other lipid molecules in the core of 
lipoproteins such as cholesteryl esters (CE). This mechanism of peroxidation agrees well 
and is supported by our experimental evidence: lag-time in the core of LDL is negatively 
correlated with the percentage of TAG in LDL and positively correlated with the 
percentage of cholesterol in LDL, in parallel to that which occurs in HDL. 
To explain the possible mechanisms underlying these findings, we refer to a study 
conducted previously in our laboratory that examined and compared the composition, 
fluidity and oxidisability of HDL hydrophobic core and amphipathic surface in two groups 
of adult males (25 kg/m2 < BMI < 30 kg/m2); the former were mixed dyslipidaemic 
patients and the latter age- and BMI-matched healthy controls. [102]. Mixed 
dyslipidaemia and metabolic syndrome have features in common, as well as potentially 
similar pathogenic mechanisms. In the current study, the levels of fat-soluble vitamins 
and the degree of unsaturation of the lipids in the core and in the surface of lipoproteins 
were not measured, because the levels of these parameters were not significantly 
different in the two groups investigated in a previous study and also did not show any 
significant correlations between these parameters. 
Dyslipidaemia changes the chemical composition, the physical characteristics and the 
response to oxidative stress in HDL [102]. These alterations are determined by a higher 
free cholesterol to phospholipid ratio in surface and TAG to CE ratio in the core and from 
higher malondialdehyde (MDA) levels and lower alpha-tocopherol and beta-carotene to 
neutral lipid ratios that cause a more rigid surface and more fluid core in HDL. These 
chemical and physical changes are accompanied by a dramatic reduction in the lag-time 
and an increase in the propagation rate of the core of HDL that testify to an increased 
susceptibility to peroxidation. These results offer some opportunity to investigate the 
changes that affect HDL in subjects with or without dyslipidaemia and alterations in lipid 
metabolism. Cazzola et al. [102] described the modification of some lipoprotein-related 
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enzymes in subjects with dyslipidaemia. In dyslipidaemic patients, the cholesterol ester 
transfer protein (CETP) was shown to promote a massive transfer of TAG from VLDL to 
HDL [70]. In the same way, the HDL-enriched in TAG was found to be more efficient in 
promoting the transfer of free cholesterol from the other lipoprotein classes and cell 
membranes to their amphipathic surface, and the TAG enrichment of HDL was shown to 
be paralleled by a decrease in lecithin-cholesterol acyltransferase (LCAT) activity 
[117,118]. These changes could justify the modifications that affect HDL in subjects with 
dyslipidaemia. 
Even if the concentrations of apolipoproteins and enzymes involved in lipoproteins 
metabolism such as apolipoproteins, LCAT and CEPT were not measured in the current 
study, the results of previous studies can explain the effect of changes in the composition 
of lipoproteins induced by diet and weight loss in our population. In fact, weight loss has 
been suggested to change the concentration and the function of different apolipoproteins 
and enzymes connected with lipoproteins. In particular, weight reduction: a) decreases 
the concentration of apolipoprotein C-III (ApoC-III) promoting the action of lipoprotein 
lipase with a reduction of TAG in HDL [93]; b) decreases the catabolism of apolipoprotein 
A-I (ApoA-I); and c) reduces CEPT levels [97,119]. ApoAI actives LCAT with a reduction 
in free cholesterol on the surface of HDL [95]. The LCAT activity promotes the formation 
of larger spherical HDL. These larger HDL are unstable and spontaneously shed a 
molecule of ApoA-I to form more stable particles, each of which now contains three 
molecules of ApoA-I instead of two molecules, further promoting this process [96]. This 
biochemical hypothesis is supported by the increased concentration of total proteins in 
HDL after weight loss. Changes in the concentration and in the activity of apolipoproteins 
and enzymes reduce the percentage of TAG in HDL core, as shown by the chemical 
analysis. Weight loss also produces a reduction in plasma levels of CEPT, interrupting the 
massive transfer of TAG from VLDL to HDL [97,119]. In this way, VLDL and LDL are 
enriched in TAG. In this study, the chemical composition of VLDL did not change after 
weight loss. Supposedly, the effects of CEPT reduction are offset by the contemporary 
reduction of Apo-CIII that promotes the action of lipoprotein lipase with a reduction of 
TAG in VLDL, as seen in HDL. 
Oxidation makes HDL proinflammatory [24], while the changes described here might 
restore their powerful anti-inflammatory action. Dietary treatment also induces 
improvements that would most likely result in a reduction of proinflammatory factors and 
the reduction of weight modifies some fundamental features to define the cardiovascular 
risk in obese subjects: a) weight loss reduces abdominal fat (waist and hip circumference 
and waist to hip ratio decreased in subjects after weight loss); b) there is a significant 
improvement in insulin resistance with a reduction of glycaemia, of insulin concentration 
and of the HOMA-IR; c) there is a significant improvement in liver function (with a 
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reduction in ALT concentration from 43 U/l to 32 U/l); d) the concentration of triglycerides 
decreases (in these subjects there is a trend of reduction from 135.1 mg/dl to 119.5 mg/dl 
although not statistically significant); and e) there is a general reduction of inflammation 
levels (CRP from 0.40 mg/dl to 0.21 mg/dl although not statistically significant). These 
modifications could lead to a reduction of proinflammatory factors in order to compensate 
or even exceed the increased susceptibility of LDL to oxidation.  
The changes described here result in a redistribution of plasma lipids in the different 
lipoproteins classes, tending towards a more physiological condition and reversing the 
alterations induced by metabolic syndrome. The lipoproteins in the blood form a dynamic 
system and the different lipoproteins interact with each other, changing their form and 
their function. The change in one of the different classes of lipoproteins causes a 
modification of all other types. HDL probably represent the initial point of change in lipid 
metabolism during weight loss. This hypothesis is supported from the evidence of a 
strong correlation between the lag-time of the envelope of HDL and the lag-time of the 
core of HDL, as well as with both of the regions of LDL, as if the resistance to the initial 
peroxidation of HDL and LDL was interdependent on one other. To sum up, after weight 
loss, the anti-atherogenic properties of HDL might appear enhanced, whereas LDL might 
seem more atherogenic and it is likely this corresponds to the recapture of a 
physiological order. On the other hand, weight loss is a process with an active phase and 
with a stabilisation phase and the adaptive response of lipoproteins may be different for 
each of these phases [85]. The process of weight loss is probably a period of greater 
fragility of obese patients, and these data should prompt researchers to consider the 
active phase of weight loss as an additional risk factor. 
Although this study has provided new useful information on the oxidisability of the 
hydrophobic core and amphipathic surface of lipoproteins after weight loss, some 
limitations may also be discussed. First, the study population was relatively small and it 
was limited to male subjects. Therefore, the conclusions should not be generalised to all 
patients with metabolic syndrome. Second, although supported by other studies in our 
laboratory [102], this work lacks measurements of fat-soluble vitamins and 
malondialdehyde. Lastly, although it is accepted that the oxidisability of lipoproteins may 
play a role in the development of atherosclerosis, the validity of the assay performed in 
vitro to predict the in vivo progression of cardiovascular disease has yet to be proven. 
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In conclusion, the results of this study seem to indicate that more detailed knowledge of 
the composition, the chemical properties and the oxidisability of both the surface and 
core of lipoproteins could be a useful additional means for better understanding of the 
mechanisms that link the changes in lipoprotein metabolism to the risk of cardiovascular 
disease in patients with metabolic syndrome following weight loss. 
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